Targeting potassium channels Kv1.3 and KCa3.1: Routes to selective immunomodulators in autoimmune disorder treatment?

Pharmacotherapy

Volumn 33, Issue 5, 2013, Pages 515-528

  Wang, Jun ^a,b   Xiang, Ming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Autoimmune disorder; KCa3.1; Kv1.3; Organ specific autoimmunities; Potassium channels; Selective immunomodulators

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; 4 [[3 (TRIFLUOROMETHYL)PHENYL]METHYL] 2H 1,4 BENZOTHIAZIN 3(4H)ONE; 5 (4 PHENOXYBUTOXY)PSORALEN; 5 (4 PHENYLBUTOXY)PSORALEN; AUTOIMMUNE DRUG FROM WENXIN GROUP 1; BETA1 INTEGRIN; CALCIUM ION; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; CHARYBDOTOXIN; CHEMOKINE RECEPTOR CCR7; CORREOLIDE; CYCLOSPORIN; CYCLOSPORIN A; DIHYDROQUINOLINE DERIVATIVE; IMMUNOMODULATING AGENT; MARGATOXIN; MAUROTOXIN; NS 6180; PAP 1; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCA3.1; POTASSIUM CHANNEL KCA3.1 BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; POTASSIUM CHANNEL KV1.3 BLOCKING AGENT; PSORA 4; SENICAPOC; STICHODACTYLA HELIANTHUS TOXIN; STICHODACTYLA HELIANTHUS TOXIN 186; STICHODACTYLA HELIANTHUS TOXIN 192; STICHODACTYLA HELIANTHUS TOXIN L5; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ASTHMA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CALCIUM TRANSPORT; COLITIS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENTERITIS; GENE DELETION; GLOMERULONEPHRITIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; LYMPHOCYTE ACTIVATION; MAST CELL; MULTIPLE SCLEROSIS; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; KV1.3 POTASSIUM CHANNEL; MOLECULAR TARGETED THERAPY; POTASSIUM CHANNEL BLOCKERS;

EID: 84879579094     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1236     Document Type: Review

References (73)

1. + channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 2008;108:1744-1773.
2. Székely A, Kitajka K, Panyi G, et al. Nutrition and immune system: certain fatty acids differently modify membrane composition and consequently kinetics of KV1.3 channels of human peripheral lymphocytes. Immunobiology 2007;212:213-227.
3. Rus H, Pardo CA, Hu L, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci USA 2005;102:11094-11099.
4. Gilhar A, Bergman R, Assay B, et al. The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model. J Invest Dermatol 2011;131:118-124.
5. Xie S, Feng J, Yu C, et al. Identification of a new specific Kv1.3 channel blocker, Ctri9577, from the scorpion Chaerilus tricostatus. Peptides 2012;36:94-99.
6. Gershwin ME, Shoenfeld Y. Cutting-edge issues in organ-specific autoimmunity. Clin Rev Allergy Immunol 2011;41:123-125.
7. + channels in T cells: an option for the treatment of multiple sclerosis? Eur J Immunol 2005;35:1023-1026.
8. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83- 99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-1175.
9. Beeton C, Wulff H, Standifer NE, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 2006;103:17414-17419.
10. + channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol 2009;157:1330-1339.
11. Lam J, Wulff H. The lymphocyte potassium channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug Dev Res 2011;72:573-584.
12. Toldi G, Bajnok A, Dobi D, et al. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis. Immunobiology 2013;218:311-316.
13. Ghanshani S, Wulff H, Miller MJ, et al. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 2000;275:37137-37149.
14. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 2004;25:280-289.
15. Beeton C, Pennington MW, Norton RS. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets 2011;10:313-321.
16. Chi V, Pennington MW, Norton RS, et al. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon 2012;59:529-546.
17. Pennington MW, Beeton C, Galea CA, et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol 2009;75:762-773.
18. Han S, Yi H, Yin SJ, et al. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. J Biol Chem 2008;283:19058-19065.
19. + channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci USA 2010;107:1541-1546.
20. Toldi G, Vásárhelyi B, Kaposi A, et al. Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels. Immunol Lett 2010;133:35-41.
21. Levite M, Cahalon L, Peretz A, et al. Extracellular K(+) and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and beta1 integrins. J Exp Med 2000;191:1167-1176.
22. Hyodo T, Oda T, Kikuchi Y, et al. Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol 2010;299:F1258-F1269.
23. Vennekamp J, Wulff H, Beeton C, et al. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 2004;65:1364-1374.
24. Schmitz A, Sankaranarayanan A, Azam P, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 2005;68:1254-1270.
25. Bodendiek SB, Mahieux C, Hänsel W, et al. 4-Phenoxybutoxy- substituted heterocycles-a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem 2009;44:1838-1852.
26. Yi H, Qiu S, Wu Y, et al. Differential molecular information of maurotoxin peptide recognizing IK(Ca) and Kv1.2 channels explored by computational simulation. BMC Struct Biol 2011;11:3.
27. Moritoki Y, Lian ZX, Wulff H, et al. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology 2007;45:314-322.
28. Nicolaou SA, Neumeier L, Takimoto K, et al. Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus. Cell Calcium 2010;47:19-28.
29. Reich EP, Cui L, Yang L, et al. Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmuneencephalomyelitis in mice. Eur J Immunol 2005;35:1027-1036.
30. Strøbaek D, Brown DT, Jenkins DP, et al. NS6180, a new K (Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br J Pharmacol 2013;168:432-444.
31. Li Z, Liu WH, Han S, et al. Selective inhibition of CCR7-effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model. J Biol Chem 2012;287:29479-29494.
32. Hao B, Chen ZW, Zhou XJ, et al. Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat. Xenobiotica 2011;41:198-211.
33. + channels and inhibits T lymphocyte proliferation. J Biol Chem 2008;283:988-997.
34. + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol 2004;173:776-786.
35. Grgic I, Wulff H, Eichler I, et al. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc 2009;41:2601-2606.
36. Wulff H, Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devel 2007;10:438-445.
37. Matheu MP, Beeton C, Garcia A, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 2008;29:602-614.
38. Ren XT, Wu WP, Xu QG, et al. Change of CCR7 and CD45RA after blocking of Kv1.3 potassium channel of CD4 + T lymphocytes in multiple sclerosis. Zhonghua Yi Xue Za Zhi 2008;88:1896-1899.
39. Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev 2009;231:59-87.
40. Tarcha EJ, Chi V, Munoz-Elias EJ, et al. Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channelinhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther 2012;342:642-653.
41. Beeton C, Pennington MW, Wulff H, et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 2005;67:1369-1381.
42. Azam P, Sankaranarayanan A, Homerick D, et al. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 2007;127:1419-1429.
43. Ren YR, Pan F, Parvez S, et al. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS ONE 2008;3:e4009.
44. Koni PA, Khanna R, Chang MC, et al. Compensatory anion currents in Kv1.3 channel-deficient thymocytes. J Biol Chem 2003;278:39443-39451.
45. Wulff H, Calabresi PA, Allie R, et al. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 2003;111:1703-1713.
46. Pereira LE, Villinger F, Wulff H, et al. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy) psoralen in rhesus macaques. Exp Biol Med (Maywood) 2007;232:1338-1354.
47. Hu L, Gocke AR, Knapp E, et al. Functional blockade of the voltage-gated potassium channel Kv1.3 mediates reversion of T effector to central memory lymphocytes through SM autoimmune disorder3/p21cip1 signaling. J Biol Chem 2012;287:1261-1268.
48. Beeton C, Wulff H, Barbaria J, et al. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 2001;98:13942-13947.
49. Gocke AR, Lebson LA, Grishkan IV, et al. Kv1.3 deletion biases T cells toward an Immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J Immunol 2012;188:5877-5886.
50. Beeton C, Wulff H, Singh S, et al. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem 2003;278:9928-9937.
51. Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel 2003;6:640-647.
52. Varga Z, Csepany T, Papp F, et al. Potassium channel expression in human CD4 + regulatory and naïve T cells from healthy subjects and multiple sclerosis patients. Immunol Lett 2009;124:95-101.
53. Raychaudhuri SP, Raychaudhuri SK, Wulff H. The voltagegated potassium channel Kv1.3 in psoriasis and psoriatic arthritis: a therapeutic target for T cell-mediated autoimmune diseases. Arthritis Rheum 2009;60:1434.
54. Al-Hazza A, Linley JE, Aziz Q, et al. Potential role of reduced basolateral potassium (IKCa3.1) channel expression in the pathogenesis of diarrhoea in ulcerative colitis. J Pathol 2012;226:463-470.
55. Simms LA, Doecke JD, Roberts RL, et al. KCNN4 gene variant is associated with ileal Crohn's disease in the Australian and New Zealandpopulation. Am J Gastroenterol 2010;105:2209-2217.
56. + -activated, intermediate conductance potassium channel. J Biol Chem 2002;277:3793-3800.
57. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009;9:440-447.
58. Escribese MM, Conde E, Martín A, et al. Therapeutic effect of all-trans-retinoic acid (at-RA) on an autoimmune nephritis experimental model: role of the VLA-4 integrin. BMC Nephrol 2007;8:3.
59. Wulff H, Kolski-Andreaco A, Sankaranarayanan A, et al. Modulators of small- and intermediate-conductance calciumactivated potassium channels and their therapeutic indications. Curr Med Chem 2007;14:1437-1457.
60. Winslow MM, Crabtree GR. Immunology. Decoding calcium signaling. Science 2005;307:56-57.
61. Weber KS, Miller MJ, Allen PM. Th17 cells exhibit a distinct calcium profile from Th1 and Th2cells and have Th1-like motility and NF-AT nuclear localization. J Immunol 2008;80:1442-1450.
62. 2+ clearance distinguish Th1 and Th2 lymphocytes. J Immunol 2000;164:1153-1160.
63. + channel KCa3.1. J Immunol 2008;180:8040-7.
64. Kaur D, Berger P, Duffy SM, et al. Co-cultivation of mast cells and Fc epsilon RI alpha+ dendritic-like cells from human hip bone marrow. Clin Exp Allergy 2005;35:226-233.
65. + channels are required for human lung mast cell migration. Thorax 2006;61:880-885.
66. + channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor. Eur J Immunol 2007;37:1653-1662.
67. + channel KCa3.1 in human lung mast cells and attenuates their migration. Eur J Immunol 2008;38:2548-2556.
68. Kumar V, Sharma A. Mast cells: emerging sentinel innate immune cells with diverse role in immunity. Mol Immunol 2010;48:14-25.
69. Brown MA, Hatfield JK. Mast cells are important modifiers of autoimmune disease: with so much evidence, why is there still controversy? Front Immunol 2012;3:147.
70. Mosca M, Carli L, d'Ascanio A, et al. Occurrence of organspecific and systemic autoimmune diseases among the firstand second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews. Clin Rheumatol 2008;27:1045-1048.
71. Gutman GA, Chandy KG, Grissmer S, et al. International union of pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005;57:473-508.
72. + channel mtKCa3.1. Biochim Biophys Acta 2010;1797:1260-1267.
73. Dutta AK, Khimji AK, Sathe M, et al. Identification and functional characterization of the intermediate-conductance Ca (2 + )-activated K(+) channel (IK-1) in biliary epithelium. Am J Physiol Gastrointest Liver Physiol 2009;297:G1009.